First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.
Treatment with lisocabtagene maraleucel led to strong and durable response rates with little serious adverse effects in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.
A single administration of lisocabtagene maraleucel provided deep and durable remissions when used as third-line treatment in patients with relapsed or refractory follicular lymphoma, including those with high-risk features.
In TRANSCEND FL, 97% of patients with relapsed or refractory follicular lymphoma treated with Breyanzi achieved a response, with 94% achieving a complete response, and 81.9% of responders in ongoing. | June 17, 2023